Send to

Choose Destination
Clin Immunol. 2013 Sep;148(3):313-21. doi: 10.1016/j.clim.2013.02.014. Epub 2013 Mar 5.

Targeting the complement system in systemic lupus erythematosus and other diseases.

Author information

Division of Rheumatology and Allergy-Immunology, North Shore-Long Island Jewish Health System, Hofstra North Shore-LIJ School of Medicine, 865 Northern Boulevard Suite 302, Great Neck, NY 11021, USA.


The importance of the complement system in the pathogenesis of systemic lupus erythematosus (SLE) has long been recognized. However, despite an unprecedented amount of SLE clinical trial activities ongoing at this time, complement inhibitors have been omitted from the therapeutic assault on this disease. We review data generated from murine lupus that provide scientific support for the study of human SLE. Also reviewed is the sole study of a complement inhibitor, eculizumab, performed in patients with SLE. We conclude with a review of other inflammatory diseases where ongoing programs might provide the groundwork for the development of complement inhibitors in SLE.


Complement; Complement inhibitors; Eculizumab; Lupus nephritis; Systemic lupus erythematosus; Treatment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center